Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Leslie Citrome, Yangchun Du & Peter J Weiden. (2019) Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatric Disease and Treatment 15, pages 2639-2646.
Read now
Read now
Leslie Citrome & Amy Weiss–Citrome. (2012) A Systematic Review of Duloxetine for Osteoarthritic Pain: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?. Postgraduate Medicine 124:1, pages 83-93.
Read now
Read now
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, Kasem Akhras, Danielle Coppola, Ella Daly, David Hough & Joseph Palumbo. (2011) Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 93-101.
Read now
Read now
Leslie Citrome. (2010) Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. Postgraduate Medicine 122:4, pages 39-48.
Read now
Read now
Leslie Citrome & Joshua T Kantrowitz. (2009) Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. Expert Review of Neurotherapeutics 9:7, pages 1045-1058.
Read now
Read now
Joshua T Kantrowitz & Leslie Citrome. (2008) Olanzapine: review of safety 2008. Expert Opinion on Drug Safety 7:6, pages 761-769.
Read now
Read now
Articles from other publishers (31)
Pavel Mohr, Jirí Masopust & Miloslav Kopeček. (2022) Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?. Frontiers in Psychiatry 12.
Crossref
Crossref
Leslie Citrome, Allitia DiBernardo & Jaskaran Singh. (2020) Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 271, pages 228-238.
Crossref
Crossref
Nicolas A. Nunez, Balwinder Singh, Francisco Romo‐Nava, Boney Joseph, Marin Veldic, Alfredo Cuellar‐Barboza, Alejandra Cabello Arreola, Jennifer L. Vande Voort, Paul Croarkin, Katherine M. Moore, Joanna Biernacka, Susan L. McElroy & Mark A. Frye. (2020) Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta‐analysis of randomized controlled trials. Bipolar Disorders 22:2, pages 109-120.
Crossref
Crossref
Leslie Citrome. (2019) Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 73:10.
Crossref
Crossref
Leslie Citrome, James C. Norton, Kathy Chi-Burris & George Demos. (2017) Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums 23:3, pages 228-238.
Crossref
Crossref
Leslie Citrome. (2017) Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 71:11, pages e13030.
Crossref
Crossref
Leslie Citrome. (2017) Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 71:7, pages e12964.
Crossref
Crossref
L. Citrome. (2015) The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International Journal of Clinical Practice 69:11, pages 1211-1220.
Crossref
Crossref
Keming Gao, Chengmei Yuan, Renrong Wu, Jun Chen, Zuowei Wang, Yiru Fang & Joseph R. Calabrese. (2015) Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neuroscience Bulletin 31:5, pages 572-588.
Crossref
Crossref
L. Citrome. (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice 69:9, pages 978-997.
Crossref
Crossref
L. Citrome. (2015) Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 69:4, pages 410-421.
Crossref
Crossref
L. Citrome. (2014) Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 68:12, pages 1429-1441.
Crossref
Crossref
Leslie Citrome, Terence A. Ketter, Josephine Cucchiaro & Antony Loebel. (2014) Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 155, pages 20-27.
Crossref
Crossref
L. Citrome. (2014) Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 68:1, pages 60-82.
Crossref
Crossref
L. Citrome. (2013) Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 67:11, pages 1089-1104.
Crossref
Crossref
Leslie Citrome, Joseph F. Goldberg & Kimberly Blanchard Portland. (2013) Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 151:2, pages 409-417.
Crossref
Crossref
Larry Alphs, Joris Berwaerts & Ibrahim Turkoz. (2013) Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response. European Neuropsychopharmacology 23:11, pages 1597-1599.
Crossref
Crossref
L. Citrome & T. A. Ketter. (2013) When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. International Journal of Clinical Practice 67:5, pages 407-411.
Crossref
Crossref
Leslie Citrome. (2012) Lurasidone for the Acute Treatment of Adults with Schizophrenia: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?. Clinical Schizophrenia & Related Psychoses 6:2, pages 76-85.
Crossref
Crossref
L. Citrome. (2012) Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 66:4, pages 356-368.
Crossref
Crossref
Renrong Wu, David E. Kemp, Martha Sajatovic, Jingping Zhao, Joseph R. Calabrese & Keming Gao. (2011) Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. Clinical Therapeutics 33:12, pages B62-B76.
Crossref
Crossref
L. Citrome. (2011) Does it work, will it work, and is it worth it? A call for papers (and reviewers) regarding effective treatments for psychiatric disorders. International Journal of Clinical Practice 65:3, pages 232-233.
Crossref
Crossref
T. A. Ketter, L. Citrome, P. W. Wang, J. L. Culver & S. Srivastava. (2011) Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. Acta Psychiatrica Scandinavica 123:3, pages 175-189.
Crossref
Crossref
L. Citrome. (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice 65:2, pages 189-210.
Crossref
Crossref
B Levitan. (2010) A Concise Display of Multiple End Points for Benefit–Risk Assessment. Clinical Pharmacology & Therapeutics 89:1, pages 56-59.
Crossref
Crossref
L. Citrome. (2010) Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?. International Journal of Clinical Practice 64:11, pages 1462-1465.
Crossref
Crossref
L. Citrome. (2010) Relative vs. absolute measures of benefit and risk: whatâs the difference?. Acta Psychiatrica Scandinavica 121:2, pages 94-102.
Crossref
Crossref
L Citrome & T A Ketter. (2009) Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. Journal of Evidence-Based Medicine 2:4, pages 220-225.
Crossref
Crossref
Leslie Citrome, Ruoyong Yang, Paul Glue & Onur N. Karayal. (2009) Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research 111:1-3, pages 39-45.
Crossref
Crossref
L. Citrome & T. A. Ketter. (2009) Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. International Journal of Clinical Practice 63:3, pages 353-359.
Crossref
Crossref
L. Citrome. (2009) Olanzapine pamoate: a stick in time?. International Journal of Clinical Practice 63:1, pages 140-150.
Crossref
Crossref